Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depression, Unipolar Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

Scopolamine in Healthy Volunteers

NCT03874130
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Scopolamine
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Jun 10, 2026, 1:53 PM EDT
Terminated Phase 3 Interventional Results available

Vortioxetine to Prevent Return of Symptoms in Children With Depression

NCT05014919
View directory record Official record
Conditions
Depression
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Long Beach, California • Atlanta, Georgia • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Jun 10, 2026, 1:53 PM EDT
Not listed Not applicable Interventional

Cognitive Control Training as an Adjunct to Behavioral Activation Therapy in the Treatment of Depression

NCT01694719
View directory record Official record
Conditions
Depression
Interventions
Brief Behavioral Activation Treatment for Depression, Cognitive Control Training
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Phase 4 Interventional

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

NCT00021528
View directory record Official record
Conditions
Depression
Interventions
citalopram, BuproprionSR, buspirone, Lithium, mirtazapine, nortriptyline, sertraline, tranylcypromine, VenlafaxineXR, Cognitive Therapy, T3 (Triiodothyronine)
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Chula Vista, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

NCT00798707
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release (DVS SR), placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Arcadia, California • Beverly Hills, California • Cerritos, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Results available

Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression

NCT01754493
View directory record Official record
Conditions
Major Depression, Irritable Bowel Syndrome
Interventions
Duloxetine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Low Intensity Ultrasound Neuromodulation of Repetitive Negative Thinking In Depression

NCT05697172
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low-intensity focused ultrasound
Other
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 4, 2024 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Not applicable Interventional

Academic-Community EPINET (AC-EPINET)

NCT04497857
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Interventions
Coordinated Specialty Care (CSC)
Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jun 10, 2026, 1:53 PM EDT
Recruiting Phase 3 Interventional

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06911112
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NBI-1065845, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Huntsville, Alabama • Glendale, California • Irvine, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Jun 10, 2026, 1:53 PM EDT
Withdrawn Early Phase 1 Interventional

Long-term Potentiation Disruption Underlying Cognitive Impairment in ECT

NCT06733558
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder II
Interventions
Electroconvulsive Therapy
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Not applicable Interventional

Stress Management and Resiliency Training for Depression vs Treatment as Usual in the Treatment of Major Depression

NCT04388748
View directory record Official record
Conditions
Major Depression
Interventions
Stress Management and Resiliency Training for Depression (SMART-D) Therapy
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Albert Lea, Minnesota • Austin, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

NCT03018340
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Jun 10, 2026, 1:53 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Online System for Identifying and Addressing Teen Depression in Primary Care

NCT04489485
View directory record Official record
Conditions
Major Depression, Dysthymia, Depressive Symptoms
Interventions
Teen Depression Module used for care
Behavioral
Lead sponsor
Total Child Health, Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Phase 3 Interventional

PUFA Augmentation in Treatment of Major Depression

NCT00067301
View directory record Official record
Conditions
Major Depression
Interventions
Polyunsaturated Fatty Acids (PUFA), Citalopram
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2008 · Synced Jun 10, 2026, 1:53 PM EDT
Active, not recruiting Not applicable Interventional

DBS for TRD With the Medtronic Summit RC+S

NCT04106466
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Medtronic Summit RC+S DBS system
Device
Lead sponsor
Helen Mayberg, MD
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder

NCT02436239
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
54
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Jun 10, 2026, 1:53 PM EDT
Recruiting Not applicable Interventional

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

NCT06878859
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Cannabis Use Disorder, Mental Disorder
Interventions
Amplification of Positivity - Cannabis Use (AMP-C)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 10, 2026, 1:53 PM EDT
Recruiting Not applicable Interventional

Treating Major Depression With Yoga Mono-therapy

NCT06091527
View directory record Official record
Conditions
Depression Mild, Depression Moderate
Interventions
Yoga practice, Education
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 10, 2026, 1:53 PM EDT
Terminated Not applicable Interventional Results available

Cysteamine Therapy for Major Depressive Disorder

NCT00715559
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
cysteamine bitartrate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Not applicable Interventional

Group Therapy for Women Prisoners With Comorbid Substance Use and Depression

NCT00606996
View directory record Official record
Conditions
Substance Abuse, Substance Dependence, Depressive Disorder
Interventions
Group interpersonal psychotherapy (IPT-G), Psychoeducation on co-occurring disorders (PSYCHOED)
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cranston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Phase 4 Interventional

Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women

NCT00375297
View directory record Official record
Conditions
Sexual Dysfunction, Depression
Interventions
sildenafil
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Jun 10, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

A Study of CX157 (TriRima) for the Treatment of Depression

NCT00739908
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CX157 (TriRima), Placebo
Drug
Lead sponsor
CeNeRx BioPharma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Birmingham, Alabama • Beverly Hills, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Jun 10, 2026, 1:53 PM EDT
Terminated Not applicable Interventional Results available

Deep Brain Stimulation for Major Depressive Disorder

NCT00617162
View directory record Official record
Conditions
Depressive Disorder, Major, Unipolar Depression
Interventions
Deep Brain Stimulation, Libra Deep Brain Stimulation System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
21 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
11
States / cities
Stanford, California • Chicago, Illinois • Worcester, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Jun 10, 2026, 1:53 PM EDT